CEP72 Divergent Transcript (CEP72-DT)

CEP72-DT (CEP72 Divergent Transcript) is a transcript from the CEP72 locus, annotated as a noncoding RNA (Transcript type: RNA Gene)[5]. It is not a protein-coding gene, and there is no evidence that it has biological function, disease association, or therapeutic relevance. The “divergent transcript” terminology refers to transcripts produced from promoters that initiate transcription in both directions (“divergent” transcription), a phenomenon that generates noncoding RNA species with limited or uncharacterized function[4][5]. No data support a role for CEP72-DT as a therapeutic target, receptor, enzyme, or biomarker. Additional context: - Studies on CEP72 (Centrosomal Protein 72) gene variants relate specifically to the coding gene, whose SNPs affect vincristine-induced peripheral neuropathy as a biomarker and are not related to the CEP72-DT transcript[1][2][3][7]. - The concept of “divergent transcript” implies the transcript may be a long non-coding RNA (lncRNA) or other noncoding RNA, but the function is generally uncharacterized unless specifically described (as in other examples like GATA3-AS1[6]). - GeneCards and other databases list CEP72-DT as an RNA gene but provide no functional annotation, disease association, or therapeutic targeting evidence[5]. Note: There is no information supporting CEP72-DT as a canonical drug target, receptor, or molecule of functional significance for therapy or disease selection; its annotation is primarily based on transcriptomic data. Information about vincristine pharmacogenomics, neuropathy risk, and biomarker status relate to the protein-coding CEP72 gene, not the divergent transcript[1][2][3][7].

Other names

CEP72-DTCEP72 divergent transcript